Johnson & Johnson Operating Margin 2006-2021 | JNJ

Current and historical operating margin for Johnson & Johnson (JNJ) over the last 10 years. The current operating profit margin for Johnson & Johnson as of September 30, 2021 is 27.87%.
Johnson & Johnson Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-09-30 $91.45B $19.59B 21.42%
2021-06-30 $89.19B $20.14B 22.58%
2021-03-31 $84.21B $17.42B 20.68%
2020-12-31 $82.58B $16.50B 19.98%
2020-09-30 $80.86B $19.07B 23.58%
2020-06-30 $80.50B $16.31B 20.27%
2020-03-31 $82.73B $19.42B 23.47%
2019-12-31 $82.06B $17.33B 21.12%
2019-09-30 $81.71B $16.23B 19.87%
2019-06-30 $81.33B $19.01B 23.37%
2019-03-31 $81.59B $16.94B 20.76%
2018-12-31 $81.58B $18.00B 22.06%
2018-09-30 $81.38B $17.44B 21.43%
2018-06-30 $80.68B $17.80B 22.07%
2018-03-31 $78.69B $17.58B 22.34%
2017-12-31 $76.45B $17.67B 23.12%
2017-09-30 $74.36B $19.44B 26.14%
2017-06-30 $72.53B $19.93B 27.48%
2017-03-31 $72.17B $20.08B 27.83%
2016-12-31 $71.89B $19.80B 27.55%
2016-09-30 $71.60B $19.24B 26.87%
2016-06-30 $70.88B $18.08B 25.51%
2016-03-31 $70.18B $18.92B 26.95%
2015-12-31 $70.07B $19.20B 27.39%
2015-09-30 $70.52B $18.14B 25.73%
2015-06-30 $71.88B $20.83B 28.98%
2015-03-31 $73.59B $20.71B 28.15%
2014-12-31 $74.33B $20.56B 27.66%
2014-09-30 $74.43B $20.61B 27.69%
2014-06-30 $73.54B $17.47B 23.75%
2014-03-31 $71.92B $16.63B 23.13%
2013-12-31 $71.31B $15.47B 21.69%
2013-09-30 $70.52B $15.82B 22.44%
2013-06-30 $69.99B $15.75B 22.50%
2013-03-31 $68.59B $12.99B 18.94%
2012-12-31 $67.22B $13.78B 20.49%
2012-09-30 $65.92B $10.99B 16.68%
2012-06-30 $64.87B $11.51B 17.74%
2012-03-31 $65.00B $12.90B 19.84%
2011-12-31 $65.03B $12.36B 19.01%
2011-09-30 $64.42B $14.27B 22.15%
2011-06-30 $63.40B $14.38B 22.68%
2011-03-31 $62.13B $15.18B 24.43%
2010-12-31 $61.59B $16.95B 27.52%
2010-09-30 $62.49B $17.32B 27.72%
2010-06-30 $62.59B $17.35B 27.72%
2010-03-31 $62.50B $17.39B 27.83%
2009-12-31 $61.90B $15.76B 25.45%
2009-09-30 $60.53B $16.67B 27.54%
2009-06-30 $61.37B $16.71B 27.23%
2009-03-31 $62.58B $16.83B 26.89%
2008-12-31 $63.75B $16.93B 26.56%
2008-09-30 $64.52B $15.74B 24.40%
2008-06-30 $63.57B $14.72B 23.16%
2008-03-31 $62.25B $14.38B 23.10%
2007-12-31 $61.10B $13.28B 21.74%
2007-09-30 $58.82B $13.66B 23.22%
2007-06-30 $57.14B $14.05B 24.59%
2007-03-31 $55.37B $13.62B 24.61%
2006-12-31 $53.32B $14.59B 27.36%
2006-09-30 $52.25B $14.38B 27.52%
2006-06-30 $51.28B $14.14B 27.58%
2006-03-31 $50.67B $13.80B 27.24%
2005-12-31 $50.51B $13.12B 25.97%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $430.061B $82.584B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $290.297B 13.76
Novo Nordisk (NVO) Denmark $259.405B 34.32
Eli Lilly (LLY) United States $234.470B 29.08
AbbVie (ABBV) United States $214.730B 9.87
Merck (MRK) United States $182.575B 12.51
Novartis AG (NVS) Switzerland $180.460B 12.99
GlaxoSmithKline (GSK) United Kingdom $114.112B 13.90